Stock Analysts

Luminex Well Poised on Pipeline Strength, Strategic Tie-Ups

On Jun 24, we issued an updated research report on Austin-based Luminex Corp LMNX – a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry. The company currently carries a Zacks Rank #2 (Buy). Over the last 60 days, the Zacks Consensus Estimate for full-year 2016 earnings moved up by 23 cents (39.6%) to 81 cents per share, as most analysts revised their estimates upward. […]

Stock Analysts

United Continental Reaches a Truce with Labor Union AFA

Chicago-based United Continental Holdings UAL , the parent company of United Airlines, recently reached an agreement with the labor union (Association of Flight Attendants or AFA), representing its flight attendants. The agreement aims to bring the carrier’s 25,000+ flight attendants into a single work group. However, there is a long way to go before the objective of the agreement is fulfilled. […]

Stock Analysts

GM Invests $290M for Upgrades at Bowling Green Assembly

General Motors Company GM announced an investment worth $290 million in its Bowling Green Assembly plant to improve and revamp the facility’s vehicle assembly operations with new technologies and processes. Of the total new investment, $153 million will be utilized for an application to participate in the Kentucky Business Incentive. […]

Stock Analysts

Teva’s Cinqaero Gets Positive CHMP View, Decision in 2H16

Teva Pharmaceutical Industries Ltd. TEVA announced that Cinqaero (reslizumab), which is under review for use as an add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment, got a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). We note that Cinqaero gained FDA approval in late Mar 2016 where it was launched under the trade name Cinqair. […]

Stock Analysts

Sanofi Inks Deal to Swap Business with Boehringer Ingelheim

Sanofi SNY announced that it has signed contracts with Boehringer Ingelheim for the strategic transaction initiated in Dec 2015 regarding an exchange of their respective businesses. The business swap comprises an exchange of Sanofi’s animal health business (Merial) with an enterprise value of €11.4 billion for Boehringer Ingelheim’s consumer healthcare (CHC) business worth €6.7 billion. However, the deal does not cover Boehringer Ingelheim’s CHC business in China […]

Stock Analysts

FormFactor Diversifies, Closes Cascade Microtech Buyout

FormFactor Inc. FORM recently completed the acquisition of Oregon-based Cascade Microtech to expand further into the semiconductor testing space. In February, FormFactor announced its plans to take over Cascade Microtech, its competitor in the semiconductor testing space, in a cash-and-stock deal, worth nearly $352 million […]

Stock Analysts

Cepheid (CPHD): New Tests Drive Growth, Competition Rife

On Jun 27, we issued an updated research report on Sunnyvale, CA-based molecular diagnostics provider – Cepheid CPHD – which develops and markets fully integrated systems for clinical and non-clinical market tests. The company currently carries a Zacks Rank #3 (Hold). Cepheid currently enjoys a strong position in the molecular diagnostics space, buoyed by escalating demand for its next-generation diagnostic products […]

Technicals

Gol Linhas (GOL) Looks Good: Stock Jumps 5.7% in Session

Gol Linhas Aereas Inteligentes SA GOL was a big mover last session, as the company saw its shares rise around 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 6.0% since Jun 14. […]